Nov 5, 4:10 PM ET
Astrana Health reported third-quarter 2026 results on November 5, 2026, with revenue of $1,023.6 million, up 7%, and net income attributable to Astrana of $13.0 million, up from $0.4 million a year earlier. The company also narrowed its full-year 2026 guidance for revenue, adjusted EBITDA and free cash flow and gave fourth-quarter guidance; the filing does not state prior guidance, so the direction of the change is not shown. For shareholders, headline profit and revenue both improved, while adjusted EPS rose 4% to $0.71.
- Q3 2026 total revenue $1,023.6 million, up 7%; adjusted EBITDA $77.2 million, up 13%
- Net income attributable to Astrana $13.0 million vs $0.4 million; diluted EPS $0.26 vs $0.01
- Adjusted EPS - diluted $0.71, up 4% from $0.68
- Full-year 2026 guidance: total revenue $3.9 billion to $4.0 billion; adjusted EBITDA $261 million to $274 million; free cash flow $107.5 million to $130 million
Read the filing on SEC.gov ↗
Sep 23, 7:30 AM ET
Astrana Health said social engineering attacks, in which threat actors impersonated company personnel and spoofed its main phone number, led to unauthorized activity in its environment. The company has determined the incident is material and believes certain private or confidential information was accessed or acquired, but the full scope remains under investigation. The company currently does not expect a material effect on its financial condition and results of operations, though it cannot yet estimate the full impact.
- Company determined the incident is material as of September 22, 2026, citing the potential confidential and sensitive nature of the data involved.
- Threat actors impersonated Company personnel and spoofed the main corporate telephone number to contact employees seeking unauthorized system access.
- Company engaged a third-party forensics firm, notified law enforcement, and is notifying state and federal regulators and payer partners.
- Company maintains cybersecurity insurance but says coverage may not be sufficient to cover all losses.
Read the filing on SEC.gov ↗
Aug 6, 4:11 PM ET
Astrana Health reported second-quarter 2026 revenue of $972.5 million, up 49% from a year earlier, and net income attributable to Astrana of $19.7 million, up 109%. The company raised its full-year 2026 adjusted EBITDA guidance to $255 million to $280 million and reaffirmed its revenue and free cash flow guidance, which points to stronger profitability for shareholders.
- Q2 2026 diluted EPS was $0.40, up 111% from $0.19; adjusted EBITDA was $68.9 million, up 43%
- Full-year 2026 adjusted EBITDA guidance is $255 million to $280 million; full-year revenue guidance of $3.8 billion to $4.1 billion was reaffirmed
- Q3 2026 revenue guidance is $1.00 billion to $1.03 billion; Q3 adjusted EBITDA guidance is $72.5 million to $77.5 million
- Care Partners income from operations fell 14% in Q2, and the Care Delivery segment posted an operating loss of $3.0 million
Read the filing on SEC.gov ↗
Jul 1, 4:15 PM ET
Astrana Health said its Chief Accounting Officer and principal accounting officer, Glenn Sobotka, will retire effective August 7, 2026, with the company saying the decision does not reflect any disagreement on operations, policies, or practices. John Vong, previously the company's Group Vice President, Accounting, will succeed him as principal accounting officer on that date. The change is administrative in nature and does not alter reported financial results.
- Glenn Sobotka retires as Chief Accounting Officer effective August 7, 2026; the agreement was reached June 25, 2026
- John Vong becomes Senior Vice President, Accounting effective July 1, 2026, and principal accounting officer on August 7, 2026
- Vong's annual base salary rises to $320,000 effective July 1, 2026; his 2026 target bonus percentage is unchanged
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
